Gilead and Tentarix Biotherapeutics announced have entered three multi-year agreements to leverage Tentarix’s Tentacles® platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Gilead said that the collaboration may provide access to next-generation, multi-specific biologics. Tentarix will receive $66M in upfront payments and an equity investment from Gilead, whilst Gilead can acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80M each.
On 7 August 2023 Gingko Bioworks and Merck announced a US$490M collaboration to improve biologic manufacturing.